Drug patent settlements between rivals: a survey
This survey provides a detailed account of patent settlements reached between brand-name drug companies and their generic rivals over the past fourteen years, and the antitrust suits and investigations initiated in response. Thirty settlements of patent litigation involving twenty drugs fall within the scope of the study. Three patterns emerge from the data. First, antitrust activity in this area has continued to expand, including more than a dozen pending antitrust suits and agency investigations. Second, repeat players have emerged. Third, settlements have grown more sophisticated, particularly through the emergence of a second wave of settlements that avoids the mistakes of the first wave.
- SSRN-id969492.pdf application/pdf 893 KB Download File
More About This Work
- Academic Units
- Center for Contract and Economic Organization
- Published Here
- December 21, 2010